Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer
Zhongliu Fangzhi Yanjiu, 2020 Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen +3 more
doaj +1 more source
Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
Zhongliu Fangzhi Yanjiu, 2021 At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj +1 more source
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis [PDF]
, 2018 Five days following the 3rd cycle of nivolumab, a monoclonal antibody, which acts as immune checkpoint inhibitor against the programmed cell death protein-1, for metastatic lung adenocarcinoma, a 56-year-old woman presented at the hospital critically ill.
Baker, E +6 more
core +2 more sources
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
Безопасность и риск фармакотерапии, 2020 The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of ...
E. V. Shubnikova +4 more
doaj +1 more source
Frontiers in Immunology, 2017 Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher +7 more
doaj +1 more source
Immune checkpoint inhibitors in renal cell carcinoma [PDF]
, 2017 The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core +1 more source
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]
, 2017 Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman +25 more
core +3 more sources
The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review
Ophthalmology and TherapyIntroduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj +1 more source
Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]
, 2018 Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core +1 more source